noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

Pharmaceuticals and Biotechnology

Compugen Ltd.

Compugen to Release Third Quarter 2026 Results on Monday, November 9, 2026
Eledon Pharmaceuticals Inc.

Eledon Pharmaceuticals Presents Phase 2 BESTOW Trial Data Showing[...]
Can Fite Biofpharma Ltd.

Can-Fite Presents Final Positive Data from Phase IIa Pancreatic Cancer[...]

Economy, Business and Finance

Eikon Therapeutics Inc.

10/26/2026 | Press release | Distributed by Public on 10/26/2026 04:27

A Phase 2/3 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapyin Participants with Stage 4 Non-Small Cell Lung Cancer (NSCLC) [TeLuRide-008]-ESMO-Poster

Read this content

Click here to read the original version at the source's official website. The text of this article is not available at the moment.

Eikon Therapeutics Inc. published this content on October 26, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on October 26, 2026 at 10:27 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]

Back